Angela Consagra

Florence, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

Journal: American journal of hematology

Published: June 25, 2026

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Journal: Blood cancer journal

Published: March 13, 2026

Myelodysplastic syndrome with concomitant SF3B1 mutation and deletion of chromosome 5 long arm: outcomes and response to treatment.

Myelodysplastic syndrome with concomitant SF3B1 mutation and deletion of chromosome 5 long arm: outcomes and response to treatment.

Journal: Haematologica

Published: December 18, 2025

How to use luspatercept and erythropoiesis-stimulating agents in low-risk myelodysplastic syndrome.

How to use luspatercept and erythropoiesis-stimulating agents in low-risk myelodysplastic syndrome.

Journal: British journal of haematology

Published: January 17, 2025

IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score.

IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score.

Journal: Blood

Published: November 04, 2024

Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS.

Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS.

Journal: HemaSphere

Published: July 23, 2024

Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents.

Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents.

Journal: Blood cancer journal

Published: May 24, 2024

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes.

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes.

Journal: HemaSphere

Published: January 05, 2024

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.

Journal: American journal of hematology

Published: January 22, 2023

PIEZO1 mutations impact on early clinical manifestations of myelodysplastic syndromes.

PIEZO1 mutations impact on early clinical manifestations of myelodysplastic syndromes.

Journal: American journal of hematology

Published: October 23, 2022

Testing for rare types of Hereditary Hemochromatosis. A genetic study of two Italian families affected by early onset iron overload.

Testing for rare types of Hereditary Hemochromatosis. A genetic study of two Italian families affected by early onset iron overload.

Journal: International journal of laboratory hematology

Published: August 22, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026